| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/5/267:00 AM | $0.03 | $0.06 | +100% | — | $101.5M | $106.3M | +4.7% | +43% | |
| Q2 '26 | 8/6/267:00 AM | $0.01 | $0.00 | -100% | +100% | $90.4M | $92.1M | +1.8% | +29% | |
| Q1 '26 | 5/7/267:00 AM | -$0.01 | $0.01GAAP | +200% | +117% | $80.0M | $83.1M | +3.9% | +38% | |
| Q4 '25 | 3/2/267:00 AM | $0.04 | $0.06GAAP | +50.0% | +300% | $84.2M | $85.8M | +1.9% | +43% | |
| Q3 '25 | 11/6/257:00 AM | $0.01 | $0.00GAAP | -100% | +100% | $74.3M | $74.4M | +0.2% | +37% | |
| Q2 '25 | 8/7/257:00 AM | -$0.03 | -$0.01GAAP | +66.7% | +90% | $64.7M | $71.5M | +10.5% | +49% | |
| Q1 '25 | 5/8/257:00 AM | -$0.04 | -$0.06GAAP | -50.0% | +57% | $57.6M | $60.1M | +4.4% | +48% |
GAAP = diluted EPS as filed with the SEC. Other EPS figures are adjusted (non-GAAP), the basis analysts estimate.